GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Politeknik Kementerian Kesehatan Banjarmasin  (4)
  • 1
    Online Resource
    Online Resource
    Autologous Stem Cell Transplantation in Multiple Myeloma Patients Over 60 Years Old
    Politeknik Kementerian Kesehatan Banjarmasin ; 2021
    In:  Medical Laboratory Technology Journal Vol. 7, No. 1 ( 2021-06-18), p. 18-
    Details
    In: Medical Laboratory Technology Journal, Politeknik Kementerian Kesehatan Banjarmasin, Vol. 7, No. 1 ( 2021-06-18), p. 18-
    Abstract: The incidence of Multiple myeloma (MM) increases with age; two-thirds of the patients are older than 65 years. Induction treatment, including new agents such as thalidomide, bortezomib, and lenalidomide followed by a conditioning regimen and upfront autologous stem cell transplantation (ASCT), has been accepted the standard treatment approach for newly diagnosed fit MM patients. We aimed to search the real-life data, the efficacy and safety of upfront ASCT following induction in patients with MM over 60 years old retrospectively. The data of MM patients who were ≥60 years old during autologous stem cell transplantation and treated at our center between 2010 and 2018 retrospectively analyzed. The study results were 63 patients included at the age of ≥ 60 years who underwent upfront ASCT. Median PFS was 15.5±2.6 months, and the median overall survival (OS) was 28.15±5 months. According to age groups, median PFS was 12±2.3 months in the 60-64 age group, 18.4±6 months in the 65-69 age group, and 26±15 months in the ≥70 age group. Median OS was 26.5±6.1 months in the 60-64 age group, 39.66±8.9 months in the 65-69 age group, and 18 months in the ≥70 age group. A significant relationship between the quantity of infused CD34+ stem cells and PFS and OS (p:0.05 and p 〈 0.00, respectively). Our study indicated that a high dose (200 mg/m2 ) melphalan could safely be used in the physically fit patients at the ages of 60-69, and a reduced amount (140 mg/m2 ) would be the appropriate dose for the patients over 70. The quantity of infused CD34+ stem cells affect elderly MM patients; mobilization dynamics are also important factors for elderly myeloma. Age itself should not consider a barrier to ASCT, and a comprehensive geriatric evaluation should perform on elderly patients
    Type of Medium: Online Resource
    ISSN: 2461-0879
    URL: Issue
    URL: Article
    DOI: 10.31964/mltj.v7i1
    DOI: 10.31964/mltj.v7i1.280
    Language: Unknown
    Publisher: Politeknik Kementerian Kesehatan Banjarmasin
    Publication Date: 2021
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Early Relapse After Autologous Stem Cell Transplantation in Multiple Myeloma is Still Prognostic in The Era of Novel Agents
    Politeknik Kementerian Kesehatan Banjarmasin ; 2020
    In:  Medical Laboratory Technology Journal Vol. 6, No. 2 ( 2020-11-29), p. 92-
    Details
    In: Medical Laboratory Technology Journal, Politeknik Kementerian Kesehatan Banjarmasin, Vol. 6, No. 2 ( 2020-11-29), p. 92-
    Abstract: Significant improvements in the prognosis of Multiple Myeloma(MM) have recently observed in the era of novel agents. Induction treatment, including new agents followed by conditioning regimen and upfront autologous stem cell transplantation(ASCT), has been accepted as the standard treatment approach for newly diagnosed eligible MM patients. Despite novel agents, upfront ASCT is still superior to conventional chemotherapy alone. Previous studies revealed that the duration between ASCT and relapse had predicted overall survival(OS), and meantime, it was widely used to determine the potential benefit from a second ASCT. However, the majority of the data collected reflects the treatment modalities before novel agents. In this study, we aimed to investigate the impact of post-transplantation early relapse(ER) on survival in the era of novel agents. The results of 155 MM patients that underwent ASCT at our center between January 2010 and May 2018 were analyzed retrospectively. The median follow-up duration was 20 months in the ER group, 27 months in the non-ER group, and 24 months in all patients. 33.3% of patients in the ER group and 71.4% of patients in the non-ER group were alive at the time of analysis. Median OS was 20.77±3.66 months in the ER group and 40.89±4.21 months in the non-ER group. We found a statistically significant relationship between the ER and the poor OS (p: 〈 0.001). Our study reveals that in the era of novel agents, ER still related to poor survival. Therefore, comprehensive studies needed to develop new strategies for early relapsed patients.
    Type of Medium: Online Resource
    ISSN: 2461-0879
    URL: Issue
    URL: Article
    DOI: 10.31964/mltj.v6i2
    DOI: 10.31964/mltj.v0i0.281
    Language: Unknown
    Publisher: Politeknik Kementerian Kesehatan Banjarmasin
    Publication Date: 2020
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Autologous Stem Cell Transplantation in Multiple Myeloma Patients Over 60 Years Old
    Politeknik Kementerian Kesehatan Banjarmasin ; 2021
    In:  Medical Laboratory Technology Journal Vol. 7, No. 1 ( 2021-06-18), p. 18-
    Details
    In: Medical Laboratory Technology Journal, Politeknik Kementerian Kesehatan Banjarmasin, Vol. 7, No. 1 ( 2021-06-18), p. 18-
    Abstract: The incidence of Multiple myeloma (MM) increases with age; two-thirds of the patients are older than 65 years. Induction treatment, including new agents such as thalidomide, bortezomib, and lenalidomide followed by a conditioning regimen and upfront autologous stem cell transplantation (ASCT), has been accepted the standard treatment approach for newly diagnosed fit MM patients. We aimed to search the real-life data, the efficacy and safety of upfront ASCT following induction in patients with MM over 60 years old retrospectively. The data of MM patients who were ≥60 years old during autologous stem cell transplantation and treated at our center between 2010 and 2018 retrospectively analyzed. The study results were 63 patients included at the age of ≥ 60 years who underwent upfront ASCT. Median PFS was 15.5±2.6 months, and the median overall survival (OS) was 28.15±5 months. According to age groups, median PFS was 12±2.3 months in the 60-64 age group, 18.4±6 months in the 65-69 age group, and 26±15 months in the ≥70 age group. Median OS was 26.5±6.1 months in the 60-64 age group, 39.66±8.9 months in the 65-69 age group, and 18 months in the ≥70 age group. A significant relationship between the quantity of infused CD34+ stem cells and PFS and OS (p:0.05 and p 〈 0.00, respectively). Our study indicated that a high dose (200 mg/m2 ) melphalan could safely be used in the physically fit patients at the ages of 60-69, and a reduced amount (140 mg/m2 ) would be the appropriate dose for the patients over 70. The quantity of infused CD34+ stem cells affect elderly MM patients; mobilization dynamics are also important factors for elderly myeloma. Age itself should not consider a barrier to ASCT, and a comprehensive geriatric evaluation should perform on elderly patients
    Type of Medium: Online Resource
    ISSN: 2461-0879
    URL: Issue
    URL: Article
    DOI: 10.31964/mltj.v7i1
    DOI: 10.31964/mltj.v0i0.280
    Language: Unknown
    Publisher: Politeknik Kementerian Kesehatan Banjarmasin
    Publication Date: 2021
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Early Relapse After Autologous Stem Cell Transplantation in Multiple Myeloma is Still Prognostic in The Era of Novel Agents
    Politeknik Kementerian Kesehatan Banjarmasin ; 2020
    In:  Medical Laboratory Technology Journal Vol. 6, No. 2 ( 2020-11-29), p. 92-
    Details
    In: Medical Laboratory Technology Journal, Politeknik Kementerian Kesehatan Banjarmasin, Vol. 6, No. 2 ( 2020-11-29), p. 92-
    Abstract: Significant improvements in the prognosis of Multiple Myeloma(MM) have recently observed in the era of novel agents. Induction treatment, including new agents followed by conditioning regimen and upfront autologous stem cell transplantation(ASCT), has been accepted as the standard treatment approach for newly diagnosed eligible MM patients. Despite novel agents, upfront ASCT is still superior to conventional chemotherapy alone. Previous studies revealed that the duration between ASCT and relapse had predicted overall survival(OS), and meantime, it was widely used to determine the potential benefit from a second ASCT. However, the majority of the data collected reflects the treatment modalities before novel agents. In this study, we aimed to investigate the impact of post-transplantation early relapse(ER) on survival in the era of novel agents. The results of 155 MM patients that underwent ASCT at our center between January 2010 and May 2018 were analyzed retrospectively. The median follow-up duration was 20 months in the ER group, 27 months in the non-ER group, and 24 months in all patients. 33.3% of patients in the ER group and 71.4% of patients in the non-ER group were alive at the time of analysis. Median OS was 20.77±3.66 months in the ER group and 40.89±4.21 months in the non-ER group. We found a statistically significant relationship between the ER and the poor OS (p: 〈 0.001). Our study reveals that in the era of novel agents, ER still related to poor survival. Therefore, comprehensive studies needed to develop new strategies for early relapsed patients.
    Type of Medium: Online Resource
    ISSN: 2461-0879
    URL: Issue
    URL: Article
    DOI: 10.31964/mltj.v6i2
    DOI: 10.31964/mltj.v6i2.281
    Language: Unknown
    Publisher: Politeknik Kementerian Kesehatan Banjarmasin
    Publication Date: 2020
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...